ABSTRACT Introduction: The optimization of enteral nutrition is a priority in preterm neonates worldwide. Probiotics are known to improve gut maturity and function in preterm neonates. To our knowledge, previous systematic reviews have not adequately assessed the effects of probiotic supplementation on enteral nutrition in preterm neonates. Objective: We assessed the evidence on effects of probiotics on enteral nutrition in preterm neonates. Design: A systematic review of randomized controlled trials (RCTs) of probiotic supplementation in preterm (gestation ,37 wk) or low-birthweight (birth weight ,2500 g) neonates was conducted. With the use of the Cochrane Neonatal Review Group strategy, we searched the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, and Cumulative Index of Nursing and Allied Health Literature databases and proceedings of Pediatric Academic Society meetings in April 2014. Results: A total of 25 RCTs (n = 5895) were included in the review. A meta-analysis (random-effects model) of data from 19 of 25 trials (n = 4527) estimated that the time to full enteral feeds was shorter in the probiotic group (mean difference: 21.54 d; 95% CI: 22.75, 20.32 d; P , 0.00001, I 2 = 93%). Other benefits included fewer episodes of feed intolerance, better weight gain and growth velocity, decreased transition time from orogastric to breast feeds, and increased postprandial mesenteric flow. There were no adverse effects of probiotic supplementation. Conclusions: Probiotics reduced the time to full enteral feeds in preterm neonates. Additional research is necessary to assess the optimal dose, duration, and probiotic strain or strains used specifically for facilitating enteral nutrition in this population.
INTRODUCTION
A recent updated Cochrane review (1) of randomized controlled trials (RCTs) 4 (24 RCTs; 5529 neonates) confirmed previous findings that probiotic supplementation significantly reduces risk of stage II or greater necrotizing enterocolitis (NEC) (RR: 0.43, 95% CI: 0.33,0.56) and all-cause mortality (RR: 0.65; 95% CI: 0.52, 0.81) in preterm neonates. These results reemphasized previous recommendations that a change in practice in favor of probiotic supplementation is needed (1) (2) (3) (4) . However, the debate about risks compared with benefits of probiotic supplementation in preterm neonates continues (5) (6) (7) . With consideration of the evidence from RCTs (1) and reports on the routine use of probiotics (8) (9) (10) (11) , we believe that it is time to shift the focus from the well-reported and -accepted benefits of probiotics in reducing risk of NEC and mortality to improving other enteral nutrition-related outcomes (e.g., facilitating feed tolerance).
A nutritional deficit and poor growth in the early postnatal period are associated with long-term neurodevelopmental impairment, short stature, and metabolic disorders in preterm neonates (12) (13) (14) (15) (16) (17) . Extrauterine growth restriction is common at discharge in extremely low-birth-weight infants (birth weight ,1000 g) and relates to their significant cumulative caloric and protein deficits during hospitalization and slower growth velocity associated with complications of prematurity (18) (19) (20) (21) (22) (23) . Therefore, the optimization of nutrition in the early postnatal life of a preterm neonate is a priority. Probiotics are known to have various potentially beneficial effects on gut function (24) and maturity (25) . Therefore, we aimed to systematically review RCTs that reporting effect of probiotic supplementation on enteral nutrition in preterm neonates. To our knowledge, previous systematic reviews have not adequately addressed this important issue (1, (26) (27) (28) .
Our primary outcome of interest was the time to establish full enteral feeds (TFEFs). Secondary outcomes included the time to regain birth weight, number of episodes of feed intolerance, and duration of hospitalization.
METHODS
Guidelines from the Cochrane Neonatal Review Group, Centre for Reviews and Dissemination (29) , and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement were followed for undertaking and reporting this systematic review and meta-analysis (30) .
Types of studies
Only RCTs were included. Retrospective studies, prospective observational studies, narrative reviews, letters, editorials, and commentaries were excluded but read to identify potential studies.
Types of participants
Preterm neonates born at a gestational age ,37 wk or of low birth weight (,2500 g) were included.
Intervention and comparison
Studies that compared enteral administration of any probiotic or probiotics commenced within the first 10 d of life and continued $7 d compared with a placebo or controls were eligible for inclusion. For RCTs in which data on nutritional outcomes were not available, authors were contacted. If there was no response, such studies were excluded. Studies that compared one type of probiotic with another and those that compared different doses of probiotics were not included.
Outcomes
Studies were included if they reported at least one of the following outcomes: 1) TFEFs.
2)
Other nutritional outcomes such as the time to regain birth weight, anthropometric measure, extrauterine growth restriction, and feed intolerance (vomiting, abdominal distension, and gastric aspirates).
Review methods

Search strategy
The 
Data extraction
All authors searched the literature independently and assessed inclusion criteria. Authors GA-J and GD independently extracted data by using a standardized data-collection form. Inconsistencies were sorted out by discussion with all authors.
Assessment of risk of bias
Risk of bias (ROB) was assessed by using the Cochrane Risk of Bias Assessment Tool (31) . Two authors (GA-J and SR) independently assessed ROB in all domains including randomnumber generation, allocation concealment, blinding of intervention and outcome assessors, completeness of follow-up, selectivity of reporting, and other potential sources of bias. For each domain, the ROB was assessed as low risk, high risk, or unclear risk based on the guidelines of the Cochrane Collaboration (31) as follows:
1) Random sequence generation: The ROB in this domain was assessed as low if random number tables or computergenerated random numbers were used. The risk was assessed as high if any other methods were used for random sequence generation. The risk was assessed as unclear when this information was not given in a clear way.
2) Allocation concealment: The ROB in this domain was assessed as low if central randomization by a third party was used. Serially numbered, opaque, sealed, and sequentially opened envelopes were also considered as low risk. The risk was assessed as high if unsealed or transparent envelopes were used or when they were not opened sequentially. The risk was assessed as unclear when this information was not given in a clear way.
3) Blinding of participants and personnel: The ROB in this domain was assessed as low if the authors clearly described that participants and personnel (e.g., health care providers, investigators, parents) were blinded. The risk was assessed as high if some or all of them were not blinded. The risk was assessed as unclear when this information was not given in a clear way.
4)
Blinding of outcome assessment: The ROB in this domain was assessed as low if the authors clearly described that (38) n = 87 (study: n = 51 compared with placebo: n = 36). Intervention: Saccharomyces boulardii compared with maltodextrin Type of milk: EBM. Type of delivery: CS, 49% (study group) compared with 38% (placebo group) Primary outcome: tolerance to S. boulardii-supplemented formula, fecal flora analysis, intestinal D xylose absorption, and fecal lipid excretion (80% power) Secondary outcomes: incidence of NEC, 9.8% compared with 16% (P = 0.5); incidence of sepsis, 5.8% compared with 8.3%
(P = 0.7) Nutritional outcome: median TFEF, 9.3 compared with 9. (47) n = 183 (study: n = 93 compared with placebo: n = 90). Intervention: B. lactis compared with placebo Type of milk: EBM/formula. Type of delivery: VD, 30% (study group) compared with 31% (placebo group) Primary outcome: incidence density of nosocomial infections from days 7-42 of life after the initiation of enteral feeding (power: 80%); no significant effect on incidence of NEC of at least stage II (2% compared with 4%; P = NS) Nutritional outcomes: no difference in mean (6SD) TFEFs (17.9 6 6.8 compared with 18.0 6 7.4 d; P = NS) 12) Al Hosni, 2011 (48) n = 101 (study: n = 50 compared with controls: n = 51). Intervention: (L. rhamnosus GG + B. infantis) compared with no probiotics Type of milk: EBM. Type of delivery: CS, 44% (study group) compared with 59% (controls) Primary outcome: percentage of infants below 10th percentile at 34 wk PMA (power: 80%) Nutritional outcome: better mean (6SD) growth velocity in study group (14.9 6 6.5 compared with 12.6 6 4.5 g/d in controls; P = 0.05). Similar daily weight gain in both groups (P = 0.06) and no significant difference in weights ,10th percentile at 34 wk PMA (27% compared with 28%; P = 0.83) 13) ChrzanowskaLiszewska, 2011 (49) n = 47 (study: n = 21 compared with placebo: n = 26). Intervention:
LGG compared with maltodextrin Type of milk: formula. Type of delivery: VD, 23% (study group) compared with 34% (controls) Primary and nutritional outcome: presence of LGG colonization in stools, somatic growth, and length of hospital stay; (80% power) Nutritional outcome: weight gain at discharge (P = 0.567); mean duration of hospital stay, 49. (52) n = 750 (study: 372 compared with placebo: 378). Intervention: L. reuteri compared with placebo Type of milk: EBM/formula. Type of delivery: noninstrumental VD, 16% (study) compared with 17% (placebo); instrumental VD, 0% (study) compared with 0.5% (placebo); elective CS, 18% (study) compared with 17% (placebo); nonselective CS, 65% (study) compared with 65% (placebo) Primary outcome: death or nosocomial infections (power: 90%) Nutritional outcomes: lesser episodes of feed intolerance: 7% compared with 10.6%; P = 0.08 with significant effects observed in subjects #1500 g (17 episodes in study group compared with 31 episodes in control group; P = 0.04); similar durations of hospitalization in both groups (20 d) (P = 0.53); for TFEFs, P = 0.134 17A) 2 Demirel, 2013 (53) n = 179 (study: n = 81 compared with controls: n = 98). Intervention: S. boulardii compared with no probiotic Type of milk: EBM/formula. Type of delivery: CS, 79.1% (study group) compared with 82.2% (controls) Primary outcome (mean 6 SD): effect of probiotic on the course of indirect hyperbilirubinemia and duration of phototherapy (1.9 6 0.86 compared with 2.6 6 0.91 d; P , 0.05) Nutritional outcome: lesser feeding intolerance in study group (20.9% compared with 47.9%; P = 0.00) 17B) Demirel, 2013 (54) n = 181 (probiotic: n = 91 compared with controls: n = 90). Intervention: S. boulardii compared with nystatin (control) Type of milk: EBM/formula. Type of delivery: CS, 79.1% (study group) compared with 82.2% (controls) Primary outcome: incidence of fungal colonization of skin and invasive fungal infection (power: 80%) Secondary outcomes: incidence of sepsis, mortality, necrotizing enterocolitis, retinopathy of prematurity, severe IVH, and bronchopulmonary dysplasia Nutritional outcome: incidence of feeding intolerance in study group (at least one episode): 20.5% compared with 44.9% (P = 0.001) (Continued) outcome assessors were blinded. The risk was assessed as high if they were not blinded. The risk was assessed as unclear when this information was not given in a clear way.
5)
Incomplete outcome data: The ROB in this domain was assessed as low if all or a majority ($80%) of participants contributed to outcome data. If some outcome data were missing, but reasons were reported, and balanced across groups, the assessment was considered low ROB. The risk was assessed as high if this was not the case. The risk was assessed as unclear when this information was not given in a clear way.
6) Selective reporting of outcomes:
The ROB in this domain was assessed as low if all outcomes prespecified in methodology were reported. The risk was assessed as high if some of the prespecified outcomes were missing in the results section. The risk was assessed as unclear when this information was not given in a clear way.
7)
Other sources of bias: The ROB in this domain was assessed as low or high based on absence or presence of any other sources of bias, as per the reviewers' judgment. Differences of opinion were resolved by consensus after a group discussion involving all authors.
Data synthesis and statistical analysis
The meta-analysis was performed with Review Manager software (version 5.2; Cochrane Collaboration, Nordic Cochrane Centre). The random-effects model was used because we anticipated clinical and statistical heterogeneity (26) . For data that were not suitable for the meta-analysis, results have been provided in table format. Mean differences and 95% CIs were calculated for continuous variables. For binary outcomes, we planned to use RRs and 95% CIs.
Prespecified subgroups
Bifidobacterium are the dominant beneficial gut flora in healthy breast-milk-fed infants (32) . Evidence has indicated that supplementation with multiple strains may be more effective than with a single strain (33, 34) . Investigators have also reported better colonization of the gut if supplementation is commenced very early in the neonatal period (35) . Therefore, we aimed to conduct the following 3 subgroup analyses: Bifidobacterium or non-Bifidobacterium strains, single-or multiple-strain usage, and early (#72 h) or late (.72 h) initiation of probiotic supplementation. Previous systematic reviews have not addressed these important issues.
Heterogeneity and assessment of publication bias
Clinical heterogeneity was assessed and reported by summarizing characteristics such as the study population, type, dose and duration of probiotic supplementation, and other characteristics. Statistical heterogeneity was estimated by using the I 2 statistic. Publication bias was assessed by using the funnel plot (36) .
RESULTS
Of 466 citations that met criteria after the initial broad database search, 25 studies (27 publications) were included in the review (Figure 1; 37-63 ). There were 3 publications from the same study population by Demirel et al. (53) (54) (55) that evaluated the effect of probiotic supplementation on different outcomes; hence, we have considered these 3 publications as a single study. The total sample size in the review was 5895 subjects with a median of 183 subjects (range: 31-1099 subjects). A total of 14 trials used a placebo (n = 3812). (48)] reported extrauterine growth restriction as the primary outcome. Other trials assessed NEC, sepsis, mortality, gut colonization, gut permeability, and other outcomes as major outcomes. Details of study participants, sample sizes, interventions, and outcomes of included RCTs are given in Table 1 .
Primary outcome
A total of 19 of 25 trials were included for the meta-analysis for the outcome of the TFEF (Table 1) . Overall, the probioticsupplemented group took less time to achieve full feeds (mean difference: 21. For all outcome comparisons, results in the study group are presented first. BBG, Bifidobacterium breve YIT4010; CS, cesarean delivery; EBM, expressed breast milk; EDD, expected date of delivery; EOS, early-onset sepsis; IVH, intraventricular hemorrhage; LGG, Lactobacillus rhamnosus GG (ATCC 53103) Gorbach and Goldin; LOS, late-onset sepsis; LS, lower segment; LSCS, lower-segment cesarean section; NEC, necrotizing enterocolitis; PDA, patent ductus arteriosus; PDHM, pasteurized donor human milk; PMA, postmenstrual age; PVL, periventricular leukomalacia; ROP, retinopathy of prematurity; TFEF, time to full enteral feed; VD, vaginal delivery.
whether single or multiple strains were used (Figure 3) . Beneficial effects were also shown in both early and late commencements of probiotics (Figure 4 ).
Secondary outcomes
Secondary nutritional outcomes reported in trials are reported in Table 1 . Probiotic supplementation was shown to reduce the duration of hospitalization (43, 50, 60, 62) , incidence of feed intolerance (37, 46, 50, 55, 60) , and duration of indirect hyperbilirubinemia (53) . The supplementation improved weight gain in the hospital (37, 46) and growth velocity (48) . None of the trials showed any adverse effects of probiotics on these or other defined outcomes.
ROB
Results of the ROB assessment are reported in Table 2 . All but one trial used some form of a random sequence generation method. Allocation concealment was achieved in 17 of 25 trials but was unclear in the remaining trials. The funnel plot for the assessment of publication bias showed a symmetrical distribution of most studies ( Figure 5 ).
DISCUSSION
Our systematic review (25 trials; 5895 preterm neonates) indicated that probiotic supplementation has beneficial effects on enteral nutrition-related outcomes. The TFEF (19 trials; 4527 neonates) was reduced significantly in the probiotic supplemented group. This improvement was noted irrespective of whether Bifidobacterium or non-Bifidobacterium strains or whether single or multiple strains were used. Beneficial effects were also shown in both early and late commencements of probiotics. Other benefits included increased weight gain and a reduced time to regain birth weight, reduced duration of hospital stay, and fewer episodes of feed intolerance.
Probiotics have the potential to improve gut maturity and the function by various pathways. Abrams and Bishop (69) first reported the influence of microorganisms on intestinal motility. They observed that both small and large intestinal transit times and gastric emptying decreased in germ-free animals. Verdu et al. (70) reported that Lactobacillus rhamnosus and Lactobacillus helvaticus supplementation normalized gastric functioning in rat models. Williams et al. (71) showed that commensals in the gut as well as probiotics improved gut motility. Indrio et al. (72) showed that infants who received Lactobacillus reuteri DSM (Deutsche Sammlung von Mikroorganismen) 17938 had shorter gastric emptying times than did infant who received a placebo. Indrio et al. (73) have also reported that L. reuteri DSM 17938 increased the proportion of electrical activity that turned into peristaltic movements in infants. Probiotics modulate gut motility possibly by their secretory products or end products of fermentation by influencing intestinal neuroendocrine factors and the influence of mediators secreted by the gut as an immune reaction (74) . Short-chain fatty acids (SCFAs) are the main end products of colonic fermentation by gut microbiota of dietary fiber. SCFAs contribute to the regulation of upper gastrointestinal motility (lower esophageal sphincter and gastric relaxation), a reduction in the gastric-emptying time, lower interdigestive acid output, and overall gut homeostasis (75) . Mechanisms of action of SCFAs on gut motility involve systemic, humoral, and neural pathways, local reflexes, and myogenic responses (76) . Butyrate plays an important role in the regulation of transepithelial fluid transport, maintaining epithelial integrity, ameliorating mucosal oxidative status, and inflammation and modulating gut motility and visceral sensitivity (77, 78) . Evidence from a small, randomized, double-blind, placebo-controlled trial indicated that probiotic supplementation significantly improved the postprandial superior mesenteric artery flow (P = 0.035) (57), which is another possible pathway by which probiotics may improve feed tolerance because a rise in the postprandial mesenteric flow is essential for food digestion (57) .
In a systematic review of adult literature, Chapman et al. (33) examined whether multiple-strain probiotics are better than single strain in improving health outcomes. The authors showed that, in 12 of 16 included studies, mixtures of probiotics had better beneficial effects than did single strains in irritable bowel syndrome, diarrhea, atopic disease, gut function, immune function, respiratory tract infections, gut microbiota modulation, inflammatory bowel disease, and Helicobacter pylori infection. Chapman et al. (33) suggested that synergistic effects of various strains may contribute to such beneficial effects. In our study, the use of multiple-strain probiotics decreased the TFEF by 1.74 d compared with that with no supplementation, whereas the use of single strains reduced the TFEF by 1.34 d. Additional RCT's are needed to address this issue in the preterm neonatal population.
Our meta-analysis showed that full enteral feeds were achieved 3.43 d sooner in the late-supplementation group than controls. In contrast, benefits were less pronounced in the early supplementation group (1.16 d). Even after a careful review of factors such as gestation, birth weight, type, dose, and duration of supplementation, and other factors, we were unable to identify reasons behind such better benefits with late supplementation.
Results from any subgroup analyses should not be overinterpreted. Unless there is strong supporting evidence, the results are best viewed as a hypothesis-generation exercise (79) . Hence, additional RCTs are essential in which early commencement is directly compared with late probiotic supplementation.
The results of one such RCT were reported by Yamasaki et al. (35) . Thirty-six very-low-birth-weight infants were randomly assigned to early (,48 h after birth) and late (.48 h after birth) supplementation with Bifidobacterium bifidum. The median (range) time to reach a feeding volume of 100 mL (per kg/d) was 10 d (7-13 d) in the early group and 11 d (10-15 d) in the late-supplementation group. The daily body weight gain was significantly higher in the early supplementation group (21.4 6 3.2 g/d compared with 18.3 6 4.0 g/d; P , 0.02). The highest colonization rate of Bifidobacterium was observed when the supplementation was started between 24 and 48 h after birth (35) . Different probiotic strains may have effects on different aspects of gut maturity and function and to different extents. Hence, large definitive trials are needed to assess specific strains for the optimization specific enteral nutrition-related primary outcomes in preterm neonates. However, because it has been proven beyond doubt that probiotic supplementation reduces risk of death and NEC, placebo controlled trials to evaluate nutritional outcomes in which the control arm receives no probiotics are unethical (26) .
Strains with a documented ability to stimulate gut motility and gastric emptying and reduce the incidence and severity of NEC such as L. reuteri DSM 17938 may be suitable for such trials (11, (80) (81) (82) (83) (84) . For example, future RCTs could compare probiotics with L. reuteri DSM 17938 with probiotics without L. reuteri DSM 17938.
For primary outcomes such as postnatal growth restriction, it is important to use standardized parenteral and enteral nutrition protocols in the trial protocol. With consideration of direct and indirect clinical and economic benefits of a reduced duration of hospital stay and parenteral nutrition, an assessment of economic benefits and long-term neurodevelopment is important.
Strengths of our study were the large sample size (n = 5895) and the fact that significant benefits were observed irrespective of the variations in patient characteristics and the probiotic strain, dose, time of commencement, and duration of supplementation. Unlike a randomized trial, which usually involves the comparison of 2 specific treatment strategies inn a defined population, the meta-analysis enabled the combination of trials with similar conceptual intents but quite different treatments (85) . For example, in a breast cancer meta-analysis in which trials with different chemotherapy combinations, doses, and durations were combined, results confirmed that polychemotherapy was effective in reducing mortality and the recurrence of cancer (86) .
Study limitations were as follows: 1) nutrition-related effects (e.g., TFEF) were not the primary outcomes in a majority of RCTs (23 of 25 RCTs); and 2) there was significant statistical heterogeneity (I 2 = 93%). Sample sizes in RCTs were calculated to ensure that the trial had adequate power to answer a query pertaining to the primary outcome of interest. Hence, a meta-analysis of secondary outcomes needs to be interpreted cautiously. Statistical heterogeneity examines whether the observed variability of effects is greater than that expected by chance alone (87) . We explored heterogeneity by conducting various sensitivity analyses (e.g., by excluding studies in which a placebo was not used and allocation concealment was not adequate. However, statistical heterogeneity continued to persist.
In conclusion, our results indicate that probiotic supplementation reduces TFEFs in preterm neonates. Such benefits and other nutritional outcomes such as weight gain, growth velocity, and the duration of hospital stay need to be explored in future RCT's. In addition, benefits of strategies such as single-compared with multiple-strain probiotics and early compared with late commencements of probiotics need to be tested in future trials.
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